Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 4,700 shares, a decrease of 91.5% from the January 31st total of 55,100 shares. Based on an average daily volume of 56,600 shares, the days-to-cover ratio is currently 0.1 days.

Enzon Pharmaceuticals Stock Up 10.0 %

Enzon Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, hitting $0.11. 131,635 shares of the company were exchanged, compared to its average volume of 107,466. The business has a fifty day moving average of $0.15 and a 200 day moving average of $0.13. Enzon Pharmaceuticals has a 1-year low of $0.06 and a 1-year high of $0.24. The company has a market capitalization of $8.16 million, a PE ratio of 11.01 and a beta of 0.26.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.